Eritromicin
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6[(2S,3R,4S,6R)-4-(dimetilamino)-3-hidroksi-6-metiloksan-2-il]oksi14-etil-7,12,13-trihidroksi-4[(2R,4R,5S,6S)-5-hidroksi-4-metoksi-4,6-dimetiloksan-2-il]oksi3,5,7,9,11,13-heksametil-1-oksaciklotetradekan-2,10-dion | |||
| Klinički podaci | |||
| Robne marke | Abboticin, Abomacetin, Ak-mycin, Akne-Mycin | ||
| AHFS/Drugs.com | Monografija | ||
| Identifikatori | |||
| CAS broj | 114-07-8 | ||
| ATC kod | D10AF02 , S01AA17 | ||
| PubChem[1][2] | 12560 | ||
| DrugBank | DB00199 | ||
| ChemSpider[3] | 12041 | ||
| KEGG[4] | C01912 
| ||
| ChEMBL[5] | CHEMBL48923
| ||
| Hemijski podaci | |||
| Formula | C37H67NO13 | ||
| Mol. masa | 733.9268 | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Fizički podaci | |||
| Tačka topljenja | 191 °C (376 °F) | ||
| Farmakokinetički podaci | |||
| Poluvreme eliminacije | 0,8 - 3 sata | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
| Način primene | Oralno; Dental; Oftalmički; Intravenozno | ||
Eritromicin je makrolidni antibiotik koji formira vrsta Streptomyces erythreus. On inhibira bakterijsku sintezu proteina vezivanjem za bakterijske -[50S]- ribozomalne podjedinice. Njegovim vezivanjem se inhibira dejstvo peptidil transferaze i time se ometa translokacija aminokiselina tokom translacije i formiranja proteina.[6][7][8][9][10]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. PMID 11294369
- ↑ Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. PMID 12789122
- ↑ Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. PMID 17585116
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
